0001455365
false
0001455365
2023-08-08
2023-08-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): August 8, 2023
Cognition
Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-40886 |
|
13-4365359 |
(State or other jurisdiction of
incorporation or organization) |
|
( Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
2500 Westchester Avenue
Purchase, NY |
|
10577 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (412) 481-2210
Not
Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class |
|
Trading Symbol |
|
Name of Exchange on Which
Registered |
Common Stock, par value $0.001 per share |
|
CGTX |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 |
Results of Operations and Financial Condition. |
On August 8, 2023, Cognition Therapeutics, Inc.
(the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023. A copy of
the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information disclosed under Item 2.02, including
Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed
to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly
set forth by specific reference in such filing.
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits
The following exhibits are being furnished herewith:
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
COGNITION THERAPEUTICS, INC. |
|
|
|
By: |
/s/ Lisa Ricciardi |
|
Name: |
Lisa Ricciardi |
|
Title: |
President and Chief Executive Officer |
|
Date: August 8, 2023
Exhibit 99.1
Cognition
Therapeutics Reports Second Quarter 2023
Financial Results and Business Update
Announced Positive Topline Results from CT1812
Phase 2 SEQUEL Study in Mild-to-Moderate Alzheimer’s Disease
Commenced
Recruitment for 540-patient Phase 2 START Trial in Early Alzheimer’s Disease
Published Data from SNAP Study Affirming Target
Engagement of Sigma-2 (σ-2) Receptor
Patient Dosing Commenced in MAGNIFY Study for
Geographic Atrophy
PURCHASE, N.Y., August 8, 2023 (GLOBE NEWSWIRE) -- Cognition
Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative
disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), today reported financial
results for the second quarter ended June 30, 2023 and provided recent business updates.
“The
first half of 2023 saw positive news from Eisai and Lilly culminating in an approval for lecanemab and BLA filing for donanemab. These
developments are exciting and speak to the advances being made in understanding disease drivers, such as amyloid-β oligomers. Cognition
Therapeutics also made progress against this target in our own R&D effort during the first half of 2023, further demonstrating the
potential of our lead oral drug candidate, CT1812 to treat degenerative diseases of the central nervous system and retina, which
remain critically underserved,” commented Lisa Ricciardi, president and CEO of Cognition Therapeutics. “We were encouraged
by the positive topline results from our SEQUEL study. In this trial, we demonstrated the impact of CT1812 on neurophysiological endpoints
such as synapse activity and connectivity as measured by quantitative electroencephalogram (qEEG). We
anticipate full study results to be available in the fourth quarter of 2023. The cornerstone of our work at Cognition is solid
science and robust data, and we continue to augment our growing body of clinical evidence with compelling insights that we believe support
our further development of CT1812.
Ms. Ricciardi added, “In building the scientific case for
CT1812, our team and leading collaborators published a major review article in the International Journal of Molecular Science Review,
which presented the mechanistic rationale for sigma-2 (σ-2) receptor modulation as a differentiated and targeted approach to protecting
key cells from damage and death in the progression of Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular
degeneration (dry AMD). Additionally, we also announced the publication of complete results from our Phase 1 SNAP study, which indicated
that CT1812 selectively engages its primary target, the σ-2 receptor, and achieves rapid displacement of amyloid-β oligomers
from synapses after just a single oral dose. Beyond CT1812’s target engagement, we have built a library of data that supports CT1812’s
ability to mitigate brain volume atrophy in our SPARC trial and early signals of cognitive benefit observed in our SHINE trial.
“We continue to advance our ongoing trials for Alzheimer’s
disease (SHINE and START), dementia with Lewy bodies (SHIMMER), and our MAGNIFY trial in people with geographic atrophy caused by dry
AMD. We believe our current equity capital and grant funding will provide the necessary resources to reach key inflection points and clinical
milestones into the third quarter of 2024,” Ms. Ricciardi concluded.
Business and Corporate Highlights
| - | Reported positive topline results from SEQUEL qEEG study |
| - | Activated the first site in the National Institute on Aging-funded 540-patient Phase 2 START study for early Alzheimer’s disease |
| - | Initiated dosing in patients with CT1812 in the MAGNIFY dry AMD study |
| - | Advanced enrollment in the 144-patient SHINE study and 120-patient SHIMMER trial |
| - | Published confirmatory evidence from the SNAP Study in Translational Neurodegeneration showing that CT1812 selectively engages
the σ-2 receptor supporting its unique and neuroprotective mechanism of action |
| - | Presented evidence supporting CT1812 impact on pathways associated with degenerative diseases at the Association for Research in Vision
and Ophthalmology and Alzheimer's Association International Conference |
| - | Appointed John Doyle (CFO) and Steven Weissman, Ph.D. (CMC), whose combined experience will be crucial as the company advances through
its ongoing Phase 2 studies and plans for future programs |
Financial Results
Cash and cash
equivalents as of June 30, 2023, were approximately $37.2 million, and total grants funds remaining from the NIA were $81.8 million.
The Company estimates that it has sufficient cash to fund operations and capital expenditures through the third quarter of 2024.
Research and development expenses were $8.5 million for the second
quarter ended June 30, 2023, compared to $9.1 million for the same period in 2022. The decrease was primarily related to non-recurring
start-up activities from the Phase 2 SHINE and SHIMMER trials.
General and administrative expenses for the second quarter ended June 30,
2023, were $3.3 million compared to $3.1 million for the three months ended June 30, 2022. The increase was primarily due to an increase
in professional fees, partially offset by lower Director & Officer Liability insurance and other expenses.
The Company reported a net loss of $4.7 million or $(0.16) per basic
and diluted share for the second quarter ended June 30, 2023, compared to a net loss of $5.8 million or $(0.25) per basic and diluted
share during the same period in 2022.
Conference Call
Cognition will host a conference call and webcast on Tuesday, August 8,
2023, at 8:00 a.m. ET, to discuss the second quarter corporate and financial update. To access the call, dial (800) 715-9871 or (646)
307-1963 for international callers and provide conference call ID number 8093818. A live webcast can be accessed here: https://edge.media-server.com/mmc/p/uk2ydsta
or on the Investors section of the company website under News & Events. Shortly following completion of the call, an archive
will be made available and will be saved for 90 days.
About Cognition
Therapeutics:
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,
small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating
our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related
macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired
in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other
current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline
can be found at https://cogrx.com/.
Forward-Looking
Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All
statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current
conditions, are forward-looking statements. These statements, including statements relating to the timing and expected results of our
clinical trials, and cash runway, involve known and unknown risks, uncertainties and other important factors that may cause our actual
results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied
by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” might,”
“will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,”
“could,” “intend,” “target,” “project,” “contemplate,” “believe,”
“estimate,” “predict,” “forecast,” “potential” or “continue” or the negative
of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections
about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These
forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions,
some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ
materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant
funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our
ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical
trials and costs related thereto; uncertainties inherent in the results of preliminary data and pre-clinical studies being predictive
of the results of clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval
of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic,
business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of
the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our
ability to defend our intellectual property; the impact of the ongoing COVID-19 pandemic on our business, supply chain and labor force;
and the risks and uncertainties described in the “Risk Factors” section of our annual and quarterly reports filed the Securities
Exchange Commission. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking
statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved
or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a
dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to
predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or
revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances
or otherwise.
Cognition Therapeutics, Inc.
Unaudited Selected Financial Data
(in thousands, except share and per share data) | |
Three Months Ended June 30, | | |
Six Months Ended June 30, | |
Consolidated Statements of Operations Data: | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Operating Expenses: | |
| | | |
| | | |
| | | |
| | |
Research and development | |
$ | 8,497 | | |
$ | 9,098 | | |
$ | 13,927 | | |
$ | 15,616 | |
General and administrative | |
| 3,320 | | |
| 3,115 | | |
| 6,863 | | |
| 6,010 | |
Total operating expenses | |
| 11,817 | | |
| 12,213 | | |
| 20,790 | | |
| 21,626 | |
Loss from operations | |
| (11,817 | ) | |
| (12,213 | ) | |
| (20,790 | ) | |
| (21,626 | ) |
Other income (expense): | |
| | | |
| | | |
| | | |
| | |
Grant income | |
| 6,925 | | |
| 6,385 | | |
| 10,351 | | |
| 12,289 | |
Other expense, net | |
| 172 | | |
| (42 | ) | |
| (443 | ) | |
| (237 | ) |
Interest expense | |
| (6 | ) | |
| (7 | ) | |
| (16 | ) | |
| (16 | ) |
Total other income, net | |
| 7,091 | | |
| 6,336 | | |
| 9,892 | | |
| 12,036 | |
Loss before income tax | |
| (4,726 | ) | |
| (5,877 | ) | |
| (10,898 | ) | |
| (9,590 | ) |
Income tax benefit | |
| — | | |
| 125 | | |
| — | | |
| — | |
Net loss | |
$ | (4,726 | ) | |
$ | (5,752 | ) | |
$ | (10,898 | ) | |
$ | (9,590 | ) |
Unrealized (loss) gain on foreign currency translation | |
| (1 | ) | |
| (3 | ) | |
| 3 | | |
| (2 | ) |
Total comprehensive loss | |
$ | (4,727 | ) | |
$ | (5,755 | ) | |
$ | (10,895 | ) | |
$ | (9,592 | ) |
Net loss per share: | |
| | | |
| | | |
| | | |
| | |
Basic | |
$ | (0.16 | ) | |
$ | (0.25 | ) | |
$ | (0.37 | ) | |
$ | (0.43 | ) |
Diluted | |
$ | (0.16 | ) | |
$ | (0.25 | ) | |
$ | (0.37 | ) | |
$ | (0.43 | ) |
Weighted-average common shares outstanding: | |
| | | |
| | | |
| | | |
| | |
Basic | |
| 29,614,822 | | |
| 22,595,359 | | |
| 29,356,144 | | |
| 22,511,636 | |
Diluted | |
| 29,614,822 | | |
| 22,595,359 | | |
| 29,356,144 | | |
| 22,511,636 | |
| |
As of | |
(in thousands) | |
June 30, 2023 | | |
December 31, 2022 | |
Consolidated Balance Sheet Data: | |
| | | |
| | |
Cash and cash equivalents | |
$ | 37,190 | | |
$ | 41,562 | |
Total assets | |
| 43,960 | | |
| 50,425 | |
Total liabilities | |
| 9,574 | | |
| 10,176 | |
Accumulated deficit | |
| (126,299 | ) | |
| (115,401 | ) |
Total stockholders’ equity | |
| 34,386 | | |
| 40,249 | |
Contact Information: | Casey McDonald (media) | Daniel Kontoh-Boateng (investors) |
Cognition Therapeutics, Inc. | Tiberend Strategic Advisors,
Inc. | Tiberend Strategic Advisors, Inc. |
info@cogrx.com | cmcdonald@tiberend.com | dboateng@tiberend.com |
v3.23.2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Cognition Therapeutics (NASDAQ:CGTX)
Historical Stock Chart
From Apr 2024 to May 2024
Cognition Therapeutics (NASDAQ:CGTX)
Historical Stock Chart
From May 2023 to May 2024